Long COVID: Clinical Presentation, Proposed Mechanisms, Management, and the Emerging Role of Hsp90 as a Therapeutic Target

Long COVID, also termed post-acute sequelae of SARS-CoV-2 infection (PASC), affects a substantial minority of people after acute COVID-19 and is now recognized as a distinct clinical entity rather than slow convalescence. This review has two aims: to critically appraise the evidence for the principal proposed mechanisms of long COVID and to evaluate whether heat shock protein 90 (Hsp90) represents a candidate molecular node that intersects several of these mechanisms and may provide a therapeutically tractable target, without implying primacy over other pathways involved in disease pathogenesis. We first summarise the clinical presentation and the diagnostic difficulty created by symptom heterogeneity and by overlap with myalgic encephalomyelitis/chronic fatigue syndrome and other post-infectious syndromes. Then the leading candidate mechanisms, including immune dysregulation, viral antigen persistence, reactivation of latent herpesviruses, autoimmunity, endothelial and microvascular dysfunction, and skeletal muscle and mitochondrial abnormality, grading the strength of the supporting human evidence and stating the principal uncertainties for each, are evaluated. Further, we discuss the roles of Hsp90 on SARS-CoV-2 replication, immune evasion, endothelial barrier dysfunction, and chaperone-directed autoimmunity. Evidence on Hsp90 inhibition is deliberately presented in both directions: several preclinical studies report reduced viral load and inflammation, whereas one inhibitor failed to reduce viral shedding and increased mortality in infected mice, indicating that Hsp90 is a potential therapeutic target because of its involvement across multiple biological processes relevant to long COVID. Management is discussed by symptom domain, with clinical evidence distinguished throughout from in vitro, in silico and animal data, and candidate repurposed agents are summarised with the highest level of evidence currently available for each. In summary, no pharmacological therapy is yet supported by adequate randomised evidence in long COVID, and the value of Hsp90 as a target will depend on isoform selectivity, treatment timing and biomarker-defined patient selection.

Authors

Institutions

Publication Details

Journal
Pandemics
Published
2026-11-12
DOI
https://doi.org/10.3390/pandemics1030017
Primary Topic
Long-Term Effects of COVID-19
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long COVID: Clinical Presentation, Proposed Mechanisms, Management, and the Emerging Role of Hsp90 as a Therapeutic Target

Xolani Henry Makhoba, Wei Lei, Sergii Krysenko, Samwel J. Nyanda
Pandemics
Long-Term Effects of COVID-19
article

Long COVID: Clinical Presentation, Proposed Mechanisms, Management, and the Emerging Role of Hsp90 as a Therapeutic Target

Xolani Henry Makhoba, Wei Lei, Sergii Krysenko, Samwel J. Nyanda
article en

Abstract

Long COVID, also termed post-acute sequelae of SARS-CoV-2 infection (PASC), affects a substantial minority of people after acute COVID-19 and is now recognized as a distinct clinical entity rather than slow convalescence. This review has two aims: to critically appraise the evidence for the principal proposed mechanisms of long COVID and to evaluate whether heat shock protein 90 (Hsp90) represents a candidate molecular node that intersects several of these mechanisms and may provide a therapeutically tractable target, without implying primacy over other pathways involved in disease pathogenesis. We first summarise the clinical presentation and the diagnostic difficulty created by symptom heterogeneity and by overlap with myalgic encephalomyelitis/chronic fatigue syndrome and other post-infectious syndromes. Then the leading candidate mechanisms, including immune dysregulation, viral antigen persistence, reactivation of latent herpesviruses, autoimmunity, endothelial and microvascular dysfunction, and skeletal muscle and mitochondrial abnormality, grading the strength of the supporting human evidence and stating the principal uncertainties for each, are evaluated. Further, we discuss the roles of Hsp90 on SARS-CoV-2 replication, immune evasion, endothelial barrier dysfunction, and chaperone-directed autoimmunity. Evidence on Hsp90 inhibition is deliberately presented in both directions: several preclinical studies report reduced viral load and inflammation, whereas one inhibitor failed to reduce viral shedding and increased mortality in infected mice, indicating that Hsp90 is a potential therapeutic target because of its involvement across multiple biological processes relevant to long COVID. Management is discussed by symptom domain, with clinical evidence distinguished throughout from in vitro, in silico and animal data, and candidate repurposed agents are summarised with the highest level of evidence currently available for each. In summary, no pharmacological therapy is yet supported by adequate randomised evidence in long COVID, and the value of Hsp90 as a target will depend on isoform selectivity, treatment timing and biomarker-defined patient selection.

PandemicsVol. 1(3)
Campbell University (US), University of South Africa (ZA), Government of Tanzania (TZ)
National Research Foundation
Good health and well-being
Long-Term Effects of COVID-19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon